Literature DB >> 32710246

Untangling the Multidisciplinary Care Web: Streamlining Care Through an Immune-Related Adverse Events (IRAE) Tumor Board.

Laura C Kennedy1,2,3, Kit Man Wong1,2,3, Nikhil V Kamat1,2,3, Ali Raza Khaki1,2,3, Shailender Bhatia1,2,3, John A Thompson1,2,3, Petros Grivas4,5,6.   

Abstract

Immune-related adverse events (IRAEs) are becoming increasingly common as the use of immune checkpoint inhibitors expands into more tumor types and treatment settings. Although the majority of IRAEs are mild and can be managed in the outpatient setting by the medical oncologist, severe IRAEs can be life threatening and often require complex care coordination among multiple providers. These providers include a variety of non-oncology specialists who have interest and expertise in managing IRAEs. Multiple systems-based solutions have been proposed in the literature, but these need to be tailored to the needs and resources of each practice setting. In this article, we highlight the challenges of IRAE care by presenting an illustrative case from our institution. We then describe the format and structure of the IRAE Tumor Board established at the University of Washington/Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Center. Finally, we discuss how this tumor board attempts to address clinical issues related to complex IRAE presentations and provide IRAE education.

Entities:  

Year:  2020        PMID: 32710246      PMCID: PMC7489785          DOI: 10.1007/s11523-020-00739-5

Source DB:  PubMed          Journal:  Target Oncol        ISSN: 1776-2596            Impact factor:   4.493


  21 in total

1.  Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

Authors:  James Larkin; Vanna Chiarion-Sileni; Rene Gonzalez; Jean-Jacques Grob; Piotr Rutkowski; Christopher D Lao; C Lance Cowey; Dirk Schadendorf; John Wagstaff; Reinhard Dummer; Pier F Ferrucci; Michael Smylie; David Hogg; Andrew Hill; Ivan Márquez-Rodas; John Haanen; Massimo Guidoboni; Michele Maio; Patrick Schöffski; Matteo S Carlino; Céleste Lebbé; Grant McArthur; Paolo A Ascierto; Gregory A Daniels; Georgina V Long; Lars Bastholt; Jasmine I Rizzo; Agnes Balogh; Andriy Moshyk; F Stephen Hodi; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2019-09-28       Impact factor: 91.245

2.  Expansion of pharmacist clinical services to optimize the management of immune checkpoint inhibitor toxicities.

Authors:  Catherine E Renna; Elizabeth N Dow; Jason J Bergsbaken; Ticiana A Leal
Journal:  J Oncol Pharm Pract       Date:  2019-06       Impact factor: 1.809

3.  Brief Report: Cancer Immunotherapy in Patients With Preexisting Rheumatic Disease: The Mayo Clinic Experience.

Authors:  Michael D Richter; Olga Pinkston; Lisa A Kottschade; Heidi D Finnes; Svetomir N Markovic; Uma Thanarajasingam
Journal:  Arthritis Rheumatol       Date:  2018-02-06       Impact factor: 10.995

Review 4.  Patient Education Issues and Strategies Associated With Immunotherapy.

Authors:  Marlon Lasa-Blandon; Kristen Stasi; Ashley Hehir; Erica Fischer-Cartlidge
Journal:  Semin Oncol Nurs       Date:  2019-08-31       Impact factor: 2.315

Review 5.  Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors.

Authors:  Laura C Kennedy; Shailender Bhatia; John A Thompson; Petros Grivas
Journal:  J Natl Compr Canc Netw       Date:  2019-06-01       Impact factor: 11.908

6.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Julie R Brahmer; Christina Lacchetti; Bryan J Schneider; Michael B Atkins; Kelly J Brassil; Jeffrey M Caterino; Ian Chau; Marc S Ernstoff; Jennifer M Gardner; Pamela Ginex; Sigrun Hallmeyer; Jennifer Holter Chakrabarty; Natasha B Leighl; Jennifer S Mammen; David F McDermott; Aung Naing; Loretta J Nastoupil; Tanyanika Phillips; Laura D Porter; Igor Puzanov; Cristina A Reichner; Bianca D Santomasso; Carole Seigel; Alexander Spira; Maria E Suarez-Almazor; Yinghong Wang; Jeffrey S Weber; Jedd D Wolchok; John A Thompson
Journal:  J Clin Oncol       Date:  2018-02-14       Impact factor: 44.544

7.  Management of Immunotherapy-Related Toxicities, Version 1.2019.

Authors:  John A Thompson; Bryan J Schneider; Julie Brahmer; Stephanie Andrews; Philippe Armand; Shailender Bhatia; Lihua E Budde; Luciano Costa; Marianne Davies; David Dunnington; Marc S Ernstoff; Matthew Frigault; Brianna Hoffner; Christopher J Hoimes; Mario Lacouture; Frederick Locke; Matthew Lunning; Nisha A Mohindra; Jarushka Naidoo; Anthony J Olszanski; Olalekan Oluwole; Sandip P Patel; Sunil Reddy; Mabel Ryder; Bianca Santomasso; Scott Shofer; Jeffrey A Sosman; Momen Wahidi; Yinghong Wang; Alyse Johnson-Chilla; Jillian L Scavone
Journal:  J Natl Compr Canc Netw       Date:  2019-03-01       Impact factor: 11.908

8.  Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial.

Authors:  Celeste Lebbé; Nicolas Meyer; Laurent Mortier; Ivan Marquez-Rodas; Caroline Robert; Piotr Rutkowski; Alexander M Menzies; Thomas Eigentler; Paolo A Ascierto; Michael Smylie; Dirk Schadendorf; Mazhar Ajaz; Inge Marie Svane; Rene Gonzalez; Linda Rollin; Jennifer Lord-Bessen; Abdel Saci; Elena Grigoryeva; Jacopo Pigozzo
Journal:  J Clin Oncol       Date:  2019-02-27       Impact factor: 44.544

9.  Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes.

Authors:  Aanika Balaji; Jiajia Zhang; Beatriz Wills; Kristen A Marrone; Hany Elmariah; Mark Yarchoan; Jacquelyn W Zimmerman; Khalid Hajjir; Deepti Venkatraman; Deborah K Armstrong; Daniel A Laheru; Ranee Mehra; Won Jin Ho; Joshua E Reuss; Joseph Heng; Paz Vellanki; Ross C Donehower; Matthias Holdhoff; Jarushka Naidoo
Journal:  J Oncol Pract       Date:  2019-08-06       Impact factor: 3.714

10.  Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs.

Authors:  Alyson Haslam; Vinay Prasad
Journal:  JAMA Netw Open       Date:  2019-05-03
View more
  3 in total

1.  Knowledge gap about immune checkpoint inhibitors among rheumatologists and medical students: a survey.

Authors:  Guilherme Ferreira Maciel da Silva; Joaquim Ivo Vasques Dantas Landim; Lucas Teixeira Dos Santos Brasil; Isabella Cabral Marinho Plens; Andressa Laura Castro Silva; Morton Aaron Scheinberg; Francisco Airton Castro Rocha
Journal:  Rheumatol Int       Date:  2020-08-07       Impact factor: 2.631

2.  Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors.

Authors:  Despina Michailidou; Ali Raza Khaki; Maria Pia Morelli; Leonidas Diamantopoulos; Namrata Singh; Petros Grivas
Journal:  Sci Rep       Date:  2021-04-27       Impact factor: 4.379

3.  Safety of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease.

Authors:  Swetha Alexander; Umang Swami; Aneet Kaur; Yubo Gao; Munazza Fatima; Meredith M Ginn; Jill E Stein; Petros Grivas; Yousef Zakharia; Namrata Singh
Journal:  Ann Transl Med       Date:  2021-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.